The requirement stipulates that the name of the medicine, its active ingredient and strength must be printed in Braille in both Arabic and English.
The MoPH has also issued the Guideline on the Braille Requirements for Labelling Information of Medicinal Products for Human Use, which defines the technical and regulatory standards for implementation.
Dr Ghanim Ali al-Mannai, Assistant Undersecretary for Healthcare Regulatory Affairs at the MoPH, affirmed that this measure forms part of the ministry’s efforts to enhance medication awareness across all segments of society, and to facilitate safe access to and use of pharmaceutical products by people who are blind or visually impaired.
He noted that this aligns with the priorities of the National Health Strategy (NHS), which seeks to improve population health and well-being, deliver excellence in healthcare services and patient experience, and promote quality, key enablers and sustainability.
Dr al-Mannai added that the ministry also aims to ensure the safe use of medicines and to improve access to information about medical products for people with visual impairments.
He further explained that the Pharmacy and Drug Control Department at the MoPH will monitor implementation at all stages of pharmaceutical product registration, including new registrations, renewals, and modification requests. Compliance will also be verified during inspection and regulatory visits carried out by the department’s teams to pharmacies and drug warehouses.